市場調查報告書
商品編碼
1237809
全球宮內節育器市場——規模、按產品、按年齡組、行業分析報告、區域展望、增長潛力、適用性、競爭對手份額和預測,2023-2032 年Intrauterine Devices Market Size, By Product, By Age Group, Industry Analysis Report, Regional Outlook, Growth Potential, Application Potential, Competitive Market Share & Forecast, 2023-2032 |
由於人們越來越傾向於計劃晚孕,預計到 2032 年,全球宮內避孕藥市場將顯著增長。
但是,與其他具有成本效益的替代品相比,宮內節育器價格昂貴,因此影響了整個市場的增長。 鑑於意外出生人數的增加、墮胎率的上升和健康狀況的下降,各國政府正在努力通過提供宮內節育器作為一種避孕選擇來提高認識並擴大婦女的能力。 它們的低滲透率,尤其是在發展中地區,受到高購置成本的阻礙。
另一方面,宮內避孕藥的使用增加是由於意外懷孕的發生率上升以及與口服藥等替代避孕方法相關的副作用,這對市場增長產生了積極影響。人們認為之前
領先的公司正在開發新的和先進的避孕方案,以提高市場競爭力。 例如,2021 年 8 月,拜耳公司獲得 FDA 批准,其宮內節育器 (IUD) Mirena 52mg 升級版可用於長達 7 年的預防妊娠。 該批准使該公司能夠加強其宮內節育器產品線,從而增加收入。
宮內節育器市場在產品、年齡組和地區方面存在分歧。
從 2023 年到 2032 年,20-24 歲年齡段的複合年增長率預計將達到 6%。 由於宣傳活動和這些裝置提供的額外健康益處,年輕成年女性越來越多地使用宮內節育器。 使用長效避孕藥,如激素宮內節育器 (IUD) 和銅,可以減少女性意外懷孕的頻率,並可能增加年輕人對避孕藥的採用。我有。
按地區劃分,預計到 2032 年北美的宮內節育器市場將顯著擴大。 北美的強大市場地位可歸因於多種因素,包括對創新避孕方法(包括宮內節育器)的普遍了解增加,以及該地區意外懷孕率立即下降。 根據美國國家生物技術信息中心 (NCBI) 的一份報告,美國每年大約有 100 萬例墮胎。 2017 年至 2019 年間,美國約有 70% 參加計劃生育計劃的女性使用了某種形式的避孕措施。
Global Intrauterine Devices Market is expected to grow considerably through 2032 owing to the increasing preference for planned delayed pregnancy.
However, the high cost of intrauterine devices as compared to the other cost-effective alternatives has put a strain on the overall market growth. In light of the increased prevalence of unwanted births, growing abortion rates, health degradation, and other factors, governments are working on expanding their capabilities by raising knowledge and offering IUDs as a contraceptive option to women. Its low adoption rate, particularly in developing areas, is hampered by its high acquisition costs.
On the other hand, the increasing usage of intrauterine devices can be credited to the rising incidence of unwanted pregnancies and the adverse effects associated with alternative contraceptive methods, such as oral pills, which has favorably impacted market growth.
Leading companies are creating new and advanced options for preventing pregnancies to score a competitive edge in the market. For instance, in August 2021, Bayer AG received FDA approval for an upgrade of the Intrauterine Device (IUD) Mirena 52 mg for a maximum of seven years of preventing pregnancy. The approval has enabled the company to enhance its intrauterine device product line, resulting in increased revenue creation.
The intrauterine devices market has been bifurcated in terms of product, age group, and region.
Based on the age group, the 20-24 age segment is slated to grow at 6% CAGR from 2023 to 2032. Young adult women are increasingly using IUDs due to awareness campaigns and additional health advantages provided by these devices. The prevalence of unwanted pregnancies among women may be reduced using long-acting contraception including hormonal intrauterine devices (IUDs) and coppers, fostering the production adoption amongst young population.
From the regional perspective, the North America intrauterine devices market is speculated to witness notable expansion by 2032. The high market position held by North America can be credited to a variety of factors, including growing public knowledge of innovative contraceptive methods including IUDs, which have resulted in an immediate drop in unplanned pregnancies in the region. According to a National Center of Biotechnology Information (NCBI) report, approximately 1 million abortions take place in the United States each year. Also, approximately 70% of female family planning recipients in the United States used some kind of contraception between 2017 and 2019.